Results 121 to 130 of about 15,603,096 (267)

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

open access: yesMolecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura   +19 more
wiley   +1 more source

Application of blockchain technology

open access: yes, 2018
Article Application of blockchain technology was published on December 1, 2018 in the journal it - Information Technology (volume 60, issue 5-6)
Mueller, Paul
core   +1 more source

Cobertura de gotas de pulverização obtida com diferentes pontas e taxas de aplicação na parte aérea da cana-de-açúcar Spray droplet coverage achieved with different nozzles and application rates in the aerial part of sugar cane

open access: yesCiência Rural, 2013
A aplicação de produtos fitosssanitários no setor sucroalcoleiro, até recentemente, estava focada principalmente no controle de plantas daninhas. Com o aparecimento da ferrugem alaranjada, como doença de importância agrícola na cultura da cana-de-açúcar,
Juliano Luiz Schneider   +4 more
doaj  

Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining

open access: yesMolecular Oncology, EarlyView.
IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis   +3 more
wiley   +1 more source

Flow Enabled Target Capture Halbach‐based magnetic enrichment increases circulating tumor cell capture from blood in metastatic cancer patients

open access: yesMolecular Oncology, EarlyView.
Pair‐wise comparison of the CellSearch and FETCH enrichment technologies for circulating tumor cells (CTCs) from metastatic breast, prostate, and small cell lung cancer patients shows an increased capture of CTCs using FETCH enrichment. The clinical implementation of circulating tumor cells (CTCs) as a predictive tool for therapy efficacy in the ...
Michiel Stevens   +6 more
wiley   +1 more source

XSEDE Technology Insertion Service Technology Evaluation Report: SafeNet OTP [PDF]

open access: yes, 2014
The Technology Investigation Service's Technology Evaluation team conducted an evaluation of the SafeNet Authentication Service's cloud based service for enterprises.
The Technology Investigation Service's Technology Evaluation Team
core  

Measuring built environment technology awareness using time-series analysis

open access: yes, 2021
Thesis: M.C.P., Massachusetts Institute of Technology, Department of Urban Studies and Planning, February, 2021Thesis: S.M. in Real Estate Development, Massachusetts Institute of Technology, Program in Real Estate Development in conjunction with the ...
Wang, Yuehan, M.C.P. Massachusetts Institute of Technology.
core  

USP29‐regulated noncanonical stabilization of the hypoxia‐inducible factor‐α in aggressive prostate cancer

open access: yesMolecular Oncology, EarlyView.
We identify USP29 as the only DUB mirroring CA9 expression, a marker of hypoxia and HIF pathway activation associated with PCA aggressiveness. USP29 stabilizes HIF‐1α and HIF‐2α via a noncanonical mechanism that is independent of PHD/pVHL activity yet relies on proteasomal regulation, establishing USP29 as a previously unrecognized regulator of hypoxic
Amelie S Schober   +16 more
wiley   +1 more source

Information Technology Newsletter July 2005

open access: yes, 2005
University of Minnesota: Office of Information Technology. (2005). Information Technology Newsletter July 2005.
University of Minnesota: Office of Information Technology
core  

Finding novel vulnerabilities of hypomorphic BRCA1 alleles

open access: yesMolecular Oncology, EarlyView.
Synthetic lethality screens performed to identify novel vulnerabilities often model complete gene loss, thereby overlooking patient‐derived hypomorphic mutations. In this study, we have performed genome‐wide CRISPR screens on BRCA1 hypomorphic mutations, showing BRCA1I26A behaves like wild‐type, while BRCA1R1699Q mimics deficiency. Furthermore, we have
Anne Schreuder   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy